Kiniksa Pharmaceuticals International Plc.'s net tangible assets is $650M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Kiniksa Pharmaceuticals International Plc. (KNSA) currently reports a net tangible assets of $650M as of June 2026. That compares with $500M in the prior-year period — up 32.1% year over year. Use the charts on this page to explore Kiniksa Pharmaceuticals International Plc.'s net tangible assets history and peer comparisons.
Kiniksa Pharmaceuticals International Plc.'s net tangible assets increased from $500M to $650M — a 32.1% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Kiniksa Pharmaceuticals International Plc. reported $650M in net tangible assets as of June 2026. That compares with $500M in the prior-year period — up 32.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current net tangible assets of $650M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Kiniksa Pharmaceuticals International Plc., and consider following KNSA for alerts when major investors trade the stock.
Kiniksa Pharmaceuticals International Plc. is classified in the Healthcare sector. On net tangible assets, it currently shows $650M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing KNSA with unrelated industries.